A5088092422- Hepatitis C virus research
- Liver Disease Diagnosis and Treatment
- interferon and immune responses
- Hepatitis B Virus Studies
- Cytokine Signaling Pathways and Interactions
- Immune Cell Function and Interaction
- Liver Diseases and Immunity
- Systemic Lupus Erythematosus Research
- T-cell and B-cell Immunology
- MicroRNA in disease regulation
- Pediatric Hepatobiliary Diseases and Treatments
- Viral gastroenteritis research and epidemiology
- Diagnosis and treatment of tuberculosis
- Escherichia coli research studies
- Phagocytosis and Immune Regulation
- Pneumocystis jirovecii pneumonia detection and treatment
- HIV-related health complications and treatments
- Helicobacter pylori-related gastroenterology studies
- Pancreatitis Pathology and Treatment
- IL-33, ST2, and ILC Pathways
- HIV/AIDS drug development and treatment
- Pharmacological Effects and Toxicity Studies
- Animal Virus Infections Studies
- Chronic Myeloid Leukemia Treatments
- Pharmacological Receptor Mechanisms and Effects
Kantonsspital Baselland
2011-2025
University of Basel
2008-2025
University Hospital of Basel
2003-2023
Harvard University
2021
University Hospital of Lausanne
2021
Beth Israel Deaconess Medical Center
2021
Zero to Three
2009
Institute for Biomedicine
2009
Hôpital Cardiologique du Haut-Lévêque
2009
Johns Hopkins Medicine
2009
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease worldwide. The current standard therapy for hepatitis (CHC) consists combination pegylated IFN alpha (pegIFNα) and ribavirin. It achieves sustained viral clearance in only 50–60% patients. To learn more about molecular mechanisms underlying treatment failure, we investigated IFN-induced signaling paired biopsies collected from CHC patients before after administration pegIFNα. In with rapid virological response to...
Abstract Mucosal-associated invariant T (MAIT) cells are innate-like that recognize microbial metabolites through a semi-invariant cell receptor (TCR). Major questions remain regarding the extent of human MAIT functional and clonal diversity. To address these, we analyzed single-cell transcriptome TCR repertoire blood liver developed RNA-sequencing, method to integrate function clonotype at resolution. diversity was comparable conventional memory cells, with private repertoires shared across...
Autoimmune hepatitis (AIH) is a rare chronic inflammatory liver disease characterized by the presence of autoantibodies, including those targeting O-phosphoseryl-tRNA:selenocysteine-tRNA synthase (SepSecS), also known as soluble antigen (SLA). Anti-SepSecS antibodies have been associated with more severe phenotype, suggesting key role for SepSecS autoantigen in AIH. To analyze immune response to patients AIH at clonal level, we combined sensitive high-throughput screening assays isolation...
Recombinant alpha interferon (IFN-α) is used for the treatment of viral hepatitis and some forms cancer. During these therapies IFN-α injected once daily or every second day several months. Recently, long-acting pegylated (pegIFN-α) has replaced standard in chronic C because it more effective, supposedly by inducing a long-lasting activation IFN signaling pathways. cultured cells, however, becomes refractory within hours, little known about pharmacodynamic effects continuously high serum...
ABSTRACT Hepatitis C virus (HCV) infection induces a state of oxidative stress by affecting mitochondrial-respiratory-chain activity. By using cell lines inducibly expressing different HCV constructs, we showed previously that viral-protein expression leads to severe impairment mitochondrial phosphorylation and major reliance on nonoxidative glucose metabolism. However, the bioenergetic competence induced cells was not compromised, indicating an efficient prosurvival adaptive response. Here,...
Hepatitis C virus (HCV) infection induces the endogenous interferon (IFN) system in liver some but not all patients with chronic hepatitis (CHC). Patients a pre-activated IFN are less likely to respond current standard therapy pegylated IFN-α. Mitochondrial antiviral signaling protein (MAVS) is an important adaptor molecule signal transduction pathway that senses viral infections and transcriptionally activates IFN-β. The HCV NS3-4A protease can cleave thereby inactivate MAVS vitro, and,...
Hepatitis C virus (HCV) infection is an important cause of chronic liver disease. Standard therapy, pegylated interferon α (pegIFNα) combined with ribavirin, results in a sustained response rate approximately half patients. The treatment failure the other patients unknown, but viral interference IFNα signal transduction through Jak-STAT pathway might be factor. We have shown previously that expression HCV proteins leads to impairment signaling because inhibition STAT1 methylation....
Mucosal-associated invariant T (MAIT) cells are the most abundant in human liver. They respond to bacterial metabolites presented by major histocompatibility complex-like molecule MR1. MAIT exert regulatory and antimicrobial functions implicated liver fibrogenesis. It is not well understood which function as antigen (Ag)-presenting for cells, under conditions stimulatory Ags reach circulation.We used different types of primary Ag-presentation assays blood-derived liver-derived cells. We...
The use of pegylated interferon-α (pegIFN-α) has replaced unmodified recombinant IFN-α for the treatment chronic viral hepatitis. While superior antiviral efficacy pegIFN-α is generally attributed to improved pharmacokinetic properties, pharmacodynamic effects in liver have not been studied. Here, we analyzed pegIFN-α–induced signaling and gene regulation paired biopsies obtained prior during first week following injection 18 patients with hepatitis C. Despite sustained high concentrations...
Background/Aims Treatment of chronic hepatitis C (CHC) with pegylated interferon α (pegIFNα) and ribavirin results in a sustained response approximately half patients. Viral interference IFNα signal transduction through the Jak-STAT pathway might be an important factor underlying treatment failure. S-adenosyl-L-methionine (SAMe) betaine potentiate signaling cultured cells that express virus (HCV) proteins, enhance inhibitory effect on HCV replicons. We have performed clinical study aim to...
The Swiss Autoimmune Hepatitis Cohort Study is a nationwide registry, initiated in 2017, that collects retrospective and prospective clinical data biological samples from patients of all ages with autoimmune hepatitis treated at hepatology centres. Here, we report the analysis first 5 years registry data.A total 291 have been enrolled, 30 whom were diagnosed before 18 age composed paediatric cohort. Paediatric cohort: median diagnosis 12.5 (range 1-17, interquartile range (IQR) 8-15), 16...
The major aim of our study was the assessment efficacy lamivudine therapy in children with chronic hepatitis B (CHB). One hundred and six CHB, from 5- to 17-years old, were administered 3 mg/kg/day, up 100 mg/day, for 48 weeks. To assess several biochemical virological parameters monitored before, during, at end treatment 24 weeks after therapy. applied resulted a statistically significant decrease ALT activity HBV replication within studied group. Biochemical responses anti-viral...
A 60-year-old female patient with longstanding left-sided ulcerative colitis presented symptoms mimicking an acute flare and developed a colonic perforation shortly after starting steroid treatment. Following left hemicolectomy Hartmann's procedure, rescue treatment infliximab was started. Within few days, the hepatic failure. Histology immunohistochemistry of specimen revealed extensive necrotizing herpes simplex virus colitis, liver biopsy demonstrated hepatitis. Sixteen days admission,...
Acute decompensation and death have been observed in patients with acute hepatitis E virus (HEV) infection preexisting liver cirrhosis. However, the clinical, laboratory histological features need to be fully characterised.Some of us recently described presentation a large panel tissue specimens. Here, we conducted case-control study investigate clinical subset HEV-related acute-on-chronic failure (ACLF) death. Each patient was matched three control histologically confirmed severe alcoholic...
Background/Aims: Treatment of chronic hepatitis C (CHC) with pegylated interferon a (pegIFNa) and ribavirin results in sustained response approximately half patients.Viral interference IFNa signal transduction through the Jak-STAT pathway might be an important factor underlying treatment failure.S-adenosyl-L-methionine (SAMe) betaine potentiate signaling cultured cells that express virus (HCV) proteins, enhance inhibitory effect on HCV replicons.We have performed clinical study aim to...